About PREDICTOMA, INC
Predictoma provides an AI-powered DCIS prognostic test for early-stage breast cancer, helping clinicians determine the likelihood of recurrence and reduce unnecessary treatments. The test is grounded in peer-reviewed research and is exceptionally accurate across all patient demographics.
AI-based prognostic test for DCISReduces unnecessary surgery and over-treatmentIdentifies early-stage risk of recurrenceAdvanced machine learning and computer vision analysisGlycolytic enzyme trafficking analysisActivity heatmapping for metabolic gradientsHIPAA-compliant and enterprise-grade security
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to PREDICTOMA, INC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.